The objectives of the Outpatient Facility are: 1. To provide a common resource for Project 1-5 The facilities of the Outpatient Clinic (OPD) are essential for the acquisition of clinical data required to accomplish the aims of the various projects. It is in the OPD that assessments of sustained engraftment, tumors response, acute and chronic GVHD, manifestations of immunodeficiency, post-engraftment infections and other complications of bone marrow transplant are made. As well as clinical evaluations, the OPD provides a means for procuring blood and tissue specimens for multiple investigators. 2. To provide a systematic approach to the evaluation and management of late complications. The incidence and severity of multiple organ toxicities after BMT is under active investigation. A systematic approach to the follow-up of all patients will allow us to determine the contribution of multiple factors (such as age, preparative regimen, type of transplant, post-transplant immunosuppression) to the risk for the toxicities observed. In addition, it is anticipated that management approaches to the complications identified will be developed and investigated. 3. To prospectively evaluate chronic GVHD A systematic evaluation of patients with chronic GVHD will be carried out. A staging system for this condition will be developed as outlined in Project 2. Patients and clinical specimens for Phase II and Phase III therapeutic studies descried in Project 2 will be obtained in the OPD.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA015396-23
Application #
5206716
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
23
Fiscal Year
1996
Total Cost
Indirect Cost
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Kasamon, Yvette L; Fuchs, Ephraim J; Zahurak, Marianna et al. (2018) Shortened-Duration Tacrolimus after Nonmyeloablative, HLA-Haploidentical Bone Marrow Transplantation. Biol Blood Marrow Transplant 24:1022-1028
Robinson, Tara M; Prince, Gabrielle T; Thoburn, Chris et al. (2018) Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients. Leuk Lymphoma 59:2801-2811
Grant, Melanie L; Bollard, Catherine M (2018) Cell therapies for hematological malignancies: don't forget non-gene-modified t cells! Blood Rev 32:203-224
Fuchs, Ephraim Joseph (2017) Related haploidentical donors are a better choice than matched unrelated donors: Point. Blood Adv 1:397-400
Kanakry, Christopher G; BolaƱos-Meade, Javier; Kasamon, Yvette L et al. (2017) Low immunosuppressive burden after HLA-matched related or unrelated BMT using posttransplantation cyclophosphamide. Blood 129:1389-1393
Kasamon, Yvette L; Ambinder, Richard F; Fuchs, Ephraim J et al. (2017) Prospective study of nonmyeloablative, HLA-mismatched unrelated BMT with high-dose posttransplantation cyclophosphamide. Blood Adv 1:288-292
Llosa, Nicolas J; Cooke, Kenneth R; Chen, Allen R et al. (2017) Reduced-Intensity Haploidentical Bone Marrow Transplantation with Post-Transplant Cyclophosphamide for Solid Tumors in Pediatric and Young Adult Patients. Biol Blood Marrow Transplant 23:2127-2136
Klein, Orly R; Buddenbaum, Jessica; Tucker, Noah et al. (2017) Nonmyeloablative Haploidentical Bone Marrow Transplantation with Post-Transplantation Cyclophosphamide for Pediatric and Young Adult Patients with High-Risk Hematologic Malignancies. Biol Blood Marrow Transplant 23:325-332
McCurdy, Shannon R; Kasamon, Yvette L; Kanakry, Christopher G et al. (2017) Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica 102:391-400

Showing the most recent 10 out of 456 publications